GUIA PRACTICA DE PLANIFICACION FAMILIAR EN AP - SAMFyC

Bibliografía
Hatcher RA, Trussel J, Stewart F, Cates W Jr, Stewart GK, Guest F, et al. Contraceptive technology,
17th rev. New York: Ardent Media; 1998.
Hatzichristou D et al. Effi cacy of tadalafi l once daily in men with diabetes mellitus and erectile
dysfunction. Diabet Med. 2008; 25(2): 138-46.
Heuser P, Tonga K, Hopkins R, Henderson M, Weatherall M, Metcalfe S, Beasley R.Specifi c oral
contraceptive use and venous thromboembolism resulting in hospital admission. N Z Med J.
2004 Nov 26;117(1206):U1176.
Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and
clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two
years. Contraception 2002;65:129–32.
Hormonal contraception: recent advances and controversies. The Practice Committee of the
American Society for Reproductive Medicine. Fertility and Sterility. Vol 82, Suppl 1, Sept
2004: S26-S32.
Ismail H, Mansour D, Singh M. Migration of Implanon. J Fam Plann Reprod Health Care 2006;32:
157-59.
Jelley M J. Contraception in Primary Care. Primary Care Case views 2001; 4(3): 113-126.
Kamischke A y Nieschlag E. Progress towards hormonal male contraception. Trends Pharmacol
Sci, 2004; 25(1): 49-57.
Kovalevsky G, Barnhart K. Norplant and Other Implantable Contraceptives. Clinical Obstetrics &
Gynecology 2001; 44(1): 92-100.
Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of
standard or continuous dosing regimens of a lowdose oral contraceptive: a randomized trial.
Contraception 2003;67:9-13.
Lawson ML, Macaluso M, Duerr A, Hortin G, Hammonn K, Blackwell R et al. Partner characteristics,
intensity of the intercourse, and semen exposure during use of the female condom. Am J of
Epidemiol 2003; 157(4): 282-288.
Lete I, Bajo J, Doval JL, Álvarez D, Haya J. Actuación práctica ante el coito de riesgo. Barcelona:
Chiesi España; 2004.
Lete I, Bermejo R, Coll C, Duenas JL, Doval JL, Martinez-Salmean J, et al. Use of contraceptive
methods in Spain: results of a national survey. Contraception 2001; 63(4): 235-8.
Lete I, Bermejo R, Coll C, Dueñas JL, Doval JL, Martínez-Salmeán J, et al. Use of contraceptives
methods in Spain: results of a nacional survey. Contraception 2001;63:235-8.
Lete I. DIU con Levonorgestrel: un futuro prometedor y ¿cercano?. Boletín de la SEC 1999; 14: 1-2.
Lete-Lasa I, editor. Curso de habilidades en anticoncepción para médicos de atención primaria y
planifi cación familiar. Madrid: Sociedad Española de Contracepción; 1999.
López LM, Grimes DA y Schulz KF. Nonhormonal drugs for contracepción in men: a systematis
review. Obstet Gynecol Surv, 2005; 60(11): 746-52.
Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure
among hypertensive women. Contraception, 2003, 67:19-24.
Lucas M. Cabello F. Introducción a la sexología clínica. Elsevier. Madrid, 2007.
Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives
and the risk of breast cancer. N Engl J Med 2002; 346(26): 2025-32.
Mascareñas L. Insertion and renoval of Implanon® Contraception 1998; 6 (58 Suppl): 79-85.
Matthiesson KL y McLachlan RI. Male hormonal contraception: concept proven, product in sight?.
Human Reprod Update, 2006; 12(4): 463-82.
Medical Eligibility Criteria for Contraceptive Use. Organización Mundial de la Salud WHO 2004; en
http://www.who.int/reproductive-health/publications/MEC_3/mec.pdf.
- 163 -